- Home
- ABSI vs RAPP Comparison
ABSI vs RAPP Comparison
Compare ABSI & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABSI | RAPP |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | 140 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ABSI | RAPP |
|---|---|---|
| Price | $8.61 | $29.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $14.90 | ★ $62.71 |
| AVG Volume (30 Days) | ★ 3.9M | 405.9K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.64 | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,534,000.00 | N/A |
| Revenue This Year | $39.03 | N/A |
| Revenue Next Year | $310.91 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $23.75 |
| 52 Week High | $12.06 | $52.93 |
Technical Indicators
Market Signals| Indicator | ABSI | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 28.49 |
| Support Level | $8.17 | $25.90 |
| Resistance Level | $11.73 | $28.42 |
| Average True Range (ATR) | 0.77 | 1.57 |
| MACD | -0.24 | 0.03 |
| Stochastic Oscillator | 10.88 | 17.93 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.